AUTHORS
Giuseppe Gaetano Loscocco, MD, PhD, Naseema Gangat, MBBS2, Paola Guglielmelli, MD, PhD3, Rong He, MD4, Valentina Boldrini5, Cinthya J Zepeda Mendoza6, Giulio Capecchi7, Animesh Pardanani, PhD, MBBS8, Fernanda Di Vaio9, Francesca Gesullo10, Elena Nacca, BSc, MsC11, Alessandro Vannucchi, MD12, Ayalew Tefferi, MD13
AFFILIATIONS
1 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
2 Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States
3 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
4 Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States
5 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
6 Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States
7 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
8 Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States
9 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
10 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
11 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
12 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
13 Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background: Polycythemia vera (PV) carries lifelong risks of thrombosis, fibrotic progression, acute myeloid leukemia (AML), and premature death, yet large, well-annotated studies of its long-term course remain limited. We report two independent 1,000-patient Mayo Clinic and Florence-CRIMM experiences describing presentation, vascular burden, transformation, survival, and associated clinical, cytogenetic, and molecular variables.
Methods: Consecutive patients with PV were retrospectively evaluated at each institution; diagnoses were reviewed according to 2022 International Consensus Classification criteria. Baseline clinical/laboratory data, cytogenetics obtained ≤1 yr, and NGS performed ≤3 yr from diagnosis were included. Cohorts were analyzed separately. Cumulative incidences of arterial thrombosis (AT), venous thrombosis (VT), myelofibrotic transformation (MF), and AML were estimated with death as a competing event. Multivariable logistic regression evaluated vascular events at/prior to diagnosis; Cox models evaluated post-diagnosis events, transformation, and overall survival (OS).
Results: The Mayo cohort included 1,000 patients (median age 62 yr; 51% male; JAK2V617F 955, exon-12 45); 261 (26%) had major thrombosis at/prior to diagnosis. Cytogenetics/NGS were available in 438/208 patients; baseline aspirin/cytoreduction/anticoagulation use was 74/53/15% among evaluable patients. Over a median 9-yr follow-up, 95 AT and 65 VT occurred; 204 patients developed MF, 44 AML, and 370 died. Cumulative incidences of MF at 10/20/30/40 yr were 12/31/39/45%; corresponding estimates were 3/7/9/12% for AML, 8/13/16/16% for AT, and 6/9/10/12% for VT. On multivariable analysis, cardiovascular (CV) risk factors were associated with AT at/prior to diagnosis (OR 4.8; p<0.01), while age ≥60 yr predicted post-diagnosis AT (HR 2.6, 1.5-4.6; p<0.01). WBC >11×109/L was associated with MF (HR 1.4, 1.1-1.9; p=0.01) and inferior OS (HR 1.6, 1.3-1.9; p=0.04). Among NGS-annotated patients, SRSF2 was associated with MF (HR 15.1, 4.5-50.7), AML (HR 46, 4.9-436), and death (HR 12.6, 4.5-35.2; all p<0.01); ASXL1 with AML (HR 5.5, 1.2-25.6; p=0.03); and IDH2 (HR 4.9, 1.4-17.2; p=0.01) and TET2 (HR 1.8, 1.1-3.1; p=0.02) with inferior OS. Abnormal karyotype was associated with MF (HR 3.5, 1.6-7.6) and death (HR 2.1, 1.3-3.5; both p<0.01).
The Florence cohort included 1,000 patients (median age 61 yr; 57% male; JAK2V617F 986, exon-12 14); 228 (23%) had major thrombosis at/prior to diagnosis. JAK2V617F variant allele frequency (VAF)/cytogenetics/NGS were available in 900/599/570 patients; baseline aspirin/cytoreduction/anticoagulation use was 92/55/6%. Over a median 8-yr follow-up, 86 AT and 80 VT occurred; 163 patients developed MF, 28 AML, and 249 died. Cumulative incidences of MF at 10/20/30 yr were 11/32/54%; corresponding estimates were 1/4/12% for AML, 9/15/18% for AT, and 8/14/17% for VT. On multivariable analysis, age ≥60 yr and CV risk factors were associated with AT at/prior to diagnosis (OR 1.7; p=0.02 and OR 2.2; p<0.01) and during follow-up (HR 1.7, 1.1-2.9; p=0.04 and HR 2.0, 1.2-3.3; p=0.01). JAK2V617F VAF ≥50% was associated with VT (HR 2.3, 1.3-4.3; p<0.01) and MF (HR 2.6, 1.2-6.4; p=0.02), and NFE2 with MF (HR 5.1, 1.3-19; p=0.02). WBC >15×109/L (HR 3.7, 1.4-9.9; p=0.01) and SRSF2 (HR 8.8, 1.1-72; p=0.04) were associated with AML, while age ≥60 yr (HR 4.8, 2.6-9; p<0.01), WBC >11×109/L (HR 2.3, 1.3-3.9; p<0.01), and TET2 (HR 2.7, 1.6-4.6; p<0.01) were associated with inferior OS.
Conclusions: Across 2,000 patients, 489 (24%) had major thrombosis at/prior to diagnosis, 367 (18.3%) developed MF, 72 (3.6%) developed AML, and 619 (31%) died. MF incidence reached 31% and 32% at 20 yr, establishing a robust benchmark for the late burden of PV. CV risk factors were independently associated with AT at/prior to diagnosis in both cohorts; TET2 showed concordant associations with inferior OS, whereas associations of rare mutations with AML were exploratory. Leukocytosis, JAK2V617F VAF, and abnormal karyotype further defined outcome-specific risk. These parallel experiences provide a comprehensive reference for patient counseling and lifelong surveillance.
DISCLOSURES
Giuseppe Gaetano Loscocco, MD, PhD: AOP Health - Honoraria; AOP, GSK, Novartis - Honoraria; Novartis - Honoraria; GSK - Honoraria; GSK - Consultancy (Includes expert testimony)